For research use only. Not for therapeutic Use.
BL-2365（Cat No.:I023471）is an experimental drug being developed for the treatment of autoimmune diseases and inflammatory conditions. It is a selective inhibitor of the Janus kinase (JAK) family of proteins, specifically targeting JAK1, which plays a critical role in the signaling pathways of pro-inflammatory cytokines. By inhibiting JAK1, BL-2365 aims to reduce the activity of immune cells that contribute to inflammation and autoimmune responses, offering potential benefits in diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). BL-2365 is currently undergoing preclinical and clinical trials to evaluate its safety and efficacy.
| Catalog Number | I023471 |
| CAS Number | 31770-74-8 |
| Synonyms | BL 2365; BL2365; BL-2365 |
| Molecular Formula | C16H20O2 |
| Purity | 98% |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (1S)-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid |
| InChI | InChI=1S/C16H20O2/c17-16(18)15-9-7-13-10-12(6-8-14(13)15)11-4-2-1-3-5-11/h6,8,10-11,15H,1-5,7,9H2,(H,17,18)/t15-/m0/s1 |
| InChIKey | BKEWDCUQDVDPHC-HNNXBMFYSA-N |
| SMILES | C1CCC(CC1)C2=CC3=C(C=C2)[C@H](CC3)C(=O)O |
| Reference | 1. Fleming JS, Bierwagen ME, Campbell JA, King SP. The effect of a new anti-inflammatory agent (5-cyclohexylindan-1-carboxylic acid (BL-2365)) on platelet aggregation. Arch Int Pharmacodyn Ther. 1972 Sep;199(1):164-71. PMID: 5072183. |
